Y-mAbs Therapeutics, Inc.
YMAB
$7.08
$0.233.36%
| Weiss Ratings | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.66 | |||
| Price History | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 14.01% | |||
| 30-Day Total Return | 31.84% | |||
| 60-Day Total Return | 41.88% | |||
| 90-Day Total Return | 28.73% | |||
| Year to Date Total Return | 47.19% | |||
| 1-Year Total Return | 62.39% | |||
| 2-Year Total Return | -58.45% | |||
| 3-Year Total Return | -86.06% | |||
| 5-Year Total Return | -68.01% | |||
| 52-Week High % Change | -35.34% | |||
| 52-Week Low % Change | 162.22% | |||
| Price | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.95 | |||
| 52-Week Low Price | $2.70 | |||
| 52-Week Low Price (Date) | Mar 24, 2023 | |||
| 52-Week High Price (Date) | May 15, 2023 | |||
| Valuation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $308.84M | |||
| Enterprise Value | 223.89M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.45 | |||
| Earnings Per Share Growth | -85.37% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.32 | |||
| Price/Book (Q) | 3.08 | |||
| Enterprise Value/Revenue (TTM) | 2.41 | |||
| Price | $7.08 | |||
| Enterprise Value/EBITDA (TTM) | -32.69 | |||
| Enterprise Value/EBIT | -29.26 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.621M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 885 8505 | |||
| Address | 230 Park Avenue New York, NY 10169 | |||
| Website | www.ymabs.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -8.23% | |||
| Profit Margin | -20.75% | |||
| Management Effectiveness | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.51% | |||
| Return on Equity | -- | |||
| Income Statement | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $92.90M | |||
| Total Revenue (TTM) | $92.90M | |||
| Revenue Per Share | $2.13 | |||
| Gross Profit (TTM) | $81.51M | |||
| EBITDA (TTM) | -$6.85M | |||
| EBIT (TTM) | -$7.65M | |||
| Net Income (TTM) | -$19.28M | |||
| Net Income Avl. to Common (TTM) | -$19.28M | |||
| Total Revenue Growth (Q YOY) | 63.15% | |||
| Earnings Growth (Q YOY) | 71.86% | |||
| EPS Diluted (TTM) | -$0.45 | |||
| EPS Diluted Growth (Q YOY) | 71.43% | |||
| Balance Sheet | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $86.57M | |||
| Cash Per Share (Q) | $1.98 | |||
| Total Current Assets (Q) | $114.86M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $100.15M | |||
| Current Ratio (Q) | 5.266 | |||
| Book Value Per Share (Q) | $2.30 | |||
| Total Assets (Q) | $128.88M | |||
| Total Current Liabilities (Q) | $21.81M | |||
| Total Debt (Q) | $1.62M | |||
| Total Liabilities (Q) | $28.73M | |||
| Total Common Equity (Q) | $100.15M | |||
| Cash Flow | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | $0.00 | |||
| Net Change in Cash (TTM) | -$27.96M | |||
| Levered Free Cash Flow (TTM) | -$8.71M | |||
| Cash from Operations (TTM) | -$27.86M | |||
